Latest news and press releases about Translational Development Acquisition Corp. (TDAC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Translational Development Acquisition Corp., founded in 2022 and headquartered in New York, New York, currently conducts no significant business operations. Its primary goal is to complete a business combination, such as a merger, amalgamation, share exchange, asset acquisition, share purchase, or reorganization, with one or more companies.
Price
| Price | $10.87 |
| Market Cap | $268M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 42.22 |
| Price / Book | 1.23 |
| EV / EBITDA | -203.40 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 3.28% |
| Return on Invested Capital | -0.84% |
| Return on Assets | 3.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CEP · CEPO · FACT · HCMA · MACI · NTWO · SZZL
Explore sector: Financial Services · Shell Companies
More sections of TDAC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks